AIM ImmunoTech Files 8-K Current Report
Ticker: AIM · Form: 8-K · Filed: Feb 28, 2025 · CIK: 946644
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
AIM ImmunoTech filed a routine 8-K on Feb 28th for an event on Feb 26th.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on February 28, 2025, reporting an event on February 26, 2025. The filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates a routine update or event disclosure by AIM ImmunoTech Inc. to the SEC, which is important for investors to stay informed about the company's regulatory compliance and any material developments.
Risk Assessment
Risk Level: low — This filing is a standard 8-K current report, which typically contains routine disclosures and does not inherently signal significant new risks.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- February 26, 2025 (date) — Earliest event date
- February 28, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for AIM ImmunoTech Inc.?
The filing is a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, indicating a disclosure of events or information deemed material by the company.
When was the earliest event reported in this filing?
The earliest event reported was on February 26, 2025.
What is the filing date of this 8-K report?
The report was filed on February 28, 2025.
What was AIM ImmunoTech Inc.'s former company name?
AIM ImmunoTech Inc.'s former name was HEMISPHERX BIOPHARMA INC.
In which state is AIM ImmunoTech Inc. incorporated?
AIM ImmunoTech Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding AIM ImmunoTech Inc. (AIM).